(Q54478532)

30 May 2018

title

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. (English)

1 reference

30 May 2018

1 reference

1 reference

Richat Abbas

1

1 reference

30 May 2018

Stephan Chalon

2

1 reference

30 May 2018

Cathie Leister

3

1 reference

30 May 2018

Myriam El Gaaloul

4

1 reference

30 May 2018

Daryl Sonnichsen

5

1 reference

30 May 2018

publication date

30 September 2012

1 reference

30 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

30 May 2018

volume

71

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

123-132

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-012-1987-7

exact match

0 references

cites work

The Abl family kinases: mechanisms of regulation and signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

QT interval correction in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Drug induced QT prolongation and torsades de pointes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

Mechanisms of drug induced QT interval prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1987-7

10.1007/S00280-012-1987-7

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018